Skip to main content
SpringerLink
Log in

Botulinum Toxin

  • Chapter
  • First Online:
Evidence-Based Procedural Dermatology

  • 1489 Accesses

Abstract

Three BoNT-A preparations dominate the international markets: Botox (aka Vistabel, Vistabex), Dysport (aka Azzalure), and Xeomin (aka Bocouture).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Carruthers J, Fagien S, Matarasso SL. Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. Plast Reconstr Surg. 2004;114 (6 Suppl):1S–22S.

    PubMed  Google Scholar 

  2. Sommer B, Bergfeld D, Sattler G. Consensus recommendations on the use of botulinum toxin type A in aesthetic medicine. J Dtsch Dermatol Ges. 2007;5 Suppl 1:S1–S29.

    PubMed  Google Scholar 

  3. Rzany B. Bericht zum 1. Expertentreffen zur Anwendung von Botulinumtoxin A in der Ästhetischen Dermatologie. Kosmetische Medizin. 2003;24:2–8.

    Google Scholar 

  4. Rzany B, Fratila A, Heckmann M. 2. Expertentreffen zur Anwendung von Botulinumtoxin A (Dysport®) in der Ästhetischen Dermatologie. Kosmetische Medizin. 2005;26:134–41.

    Google Scholar 

  5. Alam M, Dover JS, Arndt KA. Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double-blind, randomized controlled trial. Arch Dermatol. 2002;138(4):510–4.

    Article  PubMed  CAS  Google Scholar 

  6. Sarifakioglu N, Sarifakioglu E. Evaluating effects of preservative-containing saline solution on pain perception during botulinum toxin type-a injections at different locations: a prospective, single-blinded, randomized controlled trial. Aesthetic Plast Surg. 2005;29(2):113–5.

    Article  PubMed  Google Scholar 

  7. Amado A, Jacob SE. Letter: benzyl alcohol preserved saline used to dilute injectables poses a risk of contact dermatitis in fragrance-sensitive patients. Dermatol Surg. 2007;33(11):1396–7.

    Article  PubMed  CAS  Google Scholar 

  8. Moy R, Maas C, Monheit G, Huber MB. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg. 2009;11(2):77–83.

    Article  PubMed  Google Scholar 

  9. Rzany B, Dill-Muller D, Grablowitz D, Heckmann M, Caird D. Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients. Dermatol Surg. 2007;33(1 Spec No.):S18–25.

    Google Scholar 

  10. Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46(6):840–9.

    Article  PubMed  Google Scholar 

  11. Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg. 2005;31(4):414–22. discussion 22.

    Article  PubMed  CAS  Google Scholar 

  12. Carruthers A, Carruthers J. Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg. 2005;31(10):1297–303.

    Article  PubMed  CAS  Google Scholar 

  13. Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg. 2003;112(4):1089–98.

    PubMed  Google Scholar 

  14. Ascher B, Zakine B, Kestemont P, Baspeyras M, Bougara A, Niforos F, et al. Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthet Surg J. 2005;25(4):365–75.

    Article  PubMed  CAS  Google Scholar 

  15. Ascher B, Zakine B, Kestemont P, Baspeyras M, Bougara A, Santini J. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol. 2004; 51(2):223–33.

    Article  PubMed  Google Scholar 

  16. Monheit G, Carruthers A, Brandt F, Rand R. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg. 2007;33(1 Spec No.):S51–9.

    Google Scholar 

  17. Rzany B, Ascher B, Fratila A, Monheit GD, Talarico S, Sterry W. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol. 2006;142(3): 320–6.

    Article  PubMed  CAS  Google Scholar 

  18. de Boulle K. Patient satisfaction with different botulinum toxin type A formulations in the treatment of moderate to severe upper facial rhytids. J Cosmet Laser Ther. 2008;10(2):87–92.

    Article  PubMed  Google Scholar 

  19. Pickett A, Rzany B. Botulinum toxin in aesthetic applications: “How often misused words generate misleading thoughts”. J Cosmet Laser Ther. 2009; 11(3):178–9.

    Article  PubMed  Google Scholar 

  20. Pickett A, Dodd S, Rzany B. Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications. J Cosmet Laser Ther. 2008;10(3):181–3.

    Article  PubMed  Google Scholar 

  21. De Maio M, Rzany B. Botulinum toxin in aesthetic medicine. Heidelberg: Springer; 2007, ISBN-10: 3540340947; ISBN-13: 978–3540340942.

    Google Scholar 

  22. Rzany B, Nast A. Head-to-head studies of botulinum toxin A in aesthetic medicine: which evidence is good enough? J Am Acad Dermatol. 2007;56(6): 1066–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Charité – Universitätsmedizin Berlin, Campus Charité mitte, Charitéplatz 1, D-10117, Berlin, Germany

    Berthold Rzany & Alexander Nast

Authors
  1. Berthold Rzany
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander Nast
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Berthold Rzany .

Editor information

Editors and Affiliations

  1. Aesthetic Surgery, Professor, Departments of Dermatology,, Chief, Section of Cutaneous and, Feinberg School of Med, Northwestern Univ, Chicago, 60611, Illinois, USA

    Murad Alam

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Rzany, B., Nast, A. (2012). Botulinum Toxin. In: Alam, M. (eds) Evidence-Based Procedural Dermatology. Springer, New York, NY. https://doi.org/10.1007/978-0-387-09424-3_19

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-09424-3_19

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-09423-6

  • Online ISBN: 978-0-387-09424-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation